AtaiBeckley announced that the Hart-Scott-Rodino waiting period for its merger with Eli Lilly has expired, and the UK competition authority has no further questions. This significantly de-risks the merger, indicating key regulatory approvals are progressing as expected, with only a short Australian waiting period remaining.
AtaiBeckley announced significant progress in its merger with Eli Lilly. The expiration of the Hart-Scott-Rodino waiting period in the US and the UK CMA's indication of no further questions are critical milestones, removing major antitrust uncertainties. This news is highly positive for AtaiBeckley shareholders as it increases the likelihood of the merger closing, providing a clear exit strategy. For Eli Lilly, it signifies smooth progress in integrating AtaiBeckley's assets. The remaining Australian waiting period is a minor hurdle, suggesting the deal is on track for timely completion, reducing execution risk for both parties and potentially boosting investor confidence in the transaction.